

Applicant : Hsu Ching-Hsaing et al.
Serial No. : 09/778,672
Filed : February 7, 2001
Page : 5

Attorney's Docket No.: 12774-002001

REMARKS

Claims 1 to 23 are cancelled without prejudice. Claims 24 to 45 are newly added. To expedite prosecution, applicant has entered related method claims that more clearly describe the invention. Support for the newly added claims can be found, e.g., in the Summary, beginning on page 1 of the specification and in previously filed claims. No new matter has been added.

The amendment to the first paragraph of the summary at page 1, line 13, corrects a typographical error.

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all claims be examined. Enclosed is a \$42.00 check for excess claim fees. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing attorney docket number 12774-002001.

Respectfully submitted,

Date: _____

12-5-01

Y. Rocky Tsao
Y. Rocky Tsao
Reg. No. 34,053

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Applicant : Hsu Ching-Hsaing et al.
Serial No. : 09/778,672
Filed : February 7, 2001
Page : 6

Attorney's Docket No.: 12774-002001

Version with Marked Changes

In the specification, the paragraph beginning at page 1, line 13 has been amended as follows:

The invention is based on the discovery that recombinant lactic acid bacteria expressing a protein allergen can induce immunological tolerance against the allergen in animal models. In addition, this tolerance was sufficient to reduce symptoms associated with exposure to the allergen, such as airway hyperreactivity and inflammation. Given the high level of unpredictability in the art of live recombinant vaccines, this [successfully] successful result was unexpected.